替吉奥单药或联合铂类治疗晚期非小细胞肺癌患者疗效与安全性的Meta评价
投稿时间:2019-02-21  修订日期:2019-05-09  点此下载全文
引用本文:
摘要点击次数: 237
全文下载次数: 0
作者单位E-mail
林莉莉 联勤保障部队第九〇〇医院药学科 liliup1215@163.com 
黄爱文 联勤保障部队第九〇〇医院药学科  
林美钦 联勤保障部队第九〇〇医院药学科  
方婕 联勤保障部队第九〇〇医院药学科  
沈钦勇 联勤保障部队第九〇〇医院药学科  
宋洪涛 联勤保障部队九〇〇医院药学科  
中文摘要:目的 探究替吉奥单药或联合铂类系统化疗方案在治疗晚期非小细胞肺癌(NSCLC)患者的疗效与安全性。方法 计算机检索CNKI、PubMed、Web of Science和Cochrane Library等数据库,纳入以替吉奥单药或联合铂类方案系统化疗为观察组,紫杉醇、多西他赛及吉西他滨单药或联合铂类化疗方案为对照组的随机临床对照试验,采用Cochrane系统评价方法进行文献质量评价, RevMan 5.3.5软件进行数据统计分析。结果 纳入25个研究,共 3977例患者。有效性方面,观察组治疗晚期NSCLC患者的有效率和疾病控制率与对照组相似,结果无统计学意义[有效率:OR=0.97,95% CI(0.83,1.13),P=0.66;疾病控制率:OR=1.11,95% CI(0.92,1.32)P=0.27]。在安全性方面,观察组相比对照组可降低多种化疗药物不良反应发生率,具有显著优势(P<0.05)。结论 晚期NSCLC患者选择系统化疗方案时,可推荐使用替吉奥单药或联合铂类化疗方案。
中文关键词:替吉奥  紫杉醇  多西他赛  吉西他滨  非小细胞肺癌  meta分析
 
The efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC: A meta-analysis
Abstract:Objective To investigate the efficacy and safety of S-1 monotherapy or combined with platinum chemotherapy in the treatment of patients with advanced NSCLC. Methods Systematic searches were performed for randomized controlled trials with the CNKI, PubMed, Web of Science and Cochrane Library. S-1 monotherapy or combined with platinum chemotherapy was the observation group, paclitaxel, docetaxel and gemcitabine monotherapy or combined with platinum chemotherapy were the control group. The Cochrane systematic review method was used for literature quality evaluation and RevMan 5.3.5 software was used for statistical analysis. Results A total of 3977 patients were enrolled in 25 studies. In terms of effectiveness, the effective rate and disease control rate of the observation group in patients with advanced NSCLC were similar to those in the control group. The results were not statistically significant [ORR: OR=0.97, 95% CI (0.83, 1.13), P=0.66; DCR: OR = 1.11, 95% CI (0.92, 1.32) P = 0.27]. In terms of safety, the experimental group can reduce the incidence of adverse reactions of multiple chemotherapy drugs compared with the control group, which has significant advantages (P< 0.05). Conclusion In patients with advanced NSCLC who choose a systemic chemotherapy regimen, S-1 monotherapy or combined with platinum chemotherapy is worth recommending.
keywords:S-1  paclitaxel  docetaxel  gemcitabine  non-small cell lung cancer  meta-analysis
  查看/发表评论  下载PDF阅读器
相关附件:   万方20190221(3.18%)  附件1  万方20190418_审稿(11.87%)
关闭

分享按钮